Contrasting MDxHealth (NASDAQ:MDXH) & Evaxion A/S (NASDAQ:EVAX)

Evaxion A/S (NASDAQ:EVAX) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, dividends, risk and profitability.

Earnings & Valuation

This table compares Evaxion A/S and MDxHealth”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53 million	3.34	-$7.71 million	($1.21)	-2.31
MDxHealth	$107.88 million	0.07	-$33.52 million	($0.72)	-0.21

Evaxion A/S has higher earnings, but lower revenue than MDxHealth. Evaxion A/S is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Evaxion A/S has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500.

Institutional and Insider Ownership

11.0% of Evaxion A/S shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 1.7% of MDxHealth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Evaxion A/S and MDxHealth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-61.43%	-34.23%
MDxHealth	-33.46%	N/A	-24.25%

Analyst Recommendations

This is a breakdown of current recommendations for Evaxion A/S and MDxHealth, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1	0	4	0	2.60
MDxHealth	1	4	1	0	2.00

Evaxion A/S currently has a consensus price target of $11.25, suggesting a potential upside of 303.23%. MDxHealth has a consensus price target of $1.33, suggesting a potential upside of 800.90%. Given MDxHealth’s higher probable upside, analysts clearly believe MDxHealth is more favorable than Evaxion A/S.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.